KIRKLAND, QC, Oct. 10, 2017 /CNW/ - Ortho Regenerative Technologies Inc. ("Ortho RTi" or the "Corporation"),an emerging Orthopaedic and Sports Medicine Technology company, will begin trading today on the Canadian Securities Exchange ("CSE") under the stock symbol "ORTH."
Ortho RTi's public listing follows a series of recent accomplishments and advancements:
In addition to these developments, Ortho RTi has grown its total headcount to 19, including 13 scientists under contract, obtained approximately $1 million non-dilutive Prima Grant, and over $12 million in funding for research and development has been invested in the technology to date.
"We are extremely proud of the progress the Ortho RTi team has made towards meeting the rapidly growing unmet medical needs in a global market." said Ortho RTi's Executive Chairman and CEO, Dr. Brent Norton. "I am confident that these recent developments will firmly positon us, as we continue to advance our proprietary biopolymer platform."
About Ortho Regenerative Technologies Inc.
Ortho RTi is an emerging Orthopaedic and Sports Medicine technology company dedicated to the development of novel therapeutic tissue repair technology to dramatically improve the success rate of sports medicine surgeries for soft tissue injuries. Our proprietary biopolymer has been specifically designed to increase the healing rates of injuries to tendons, meniscus and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Visit us on the internet at www.orthorti.com.
This news release may contain certain forward-looking statements regarding the Corporation's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Corporation disclaims any intention or obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.
SOURCE Ortho Regenerative Technologies Inc.
Subscribe to our Free Newsletters!
Erythropoietin is a hormone secreted by kidneys in response to low oxygen levels in tissues ...
Local anesthesia is a type of anesthesia generally used to block pain sensation only in a specific ...
Sea food allergy is the adverse response of the body''s immune system to the proteins present in ...View All